Antiviral Lectins from Red and Blue-Green Algae Show Potent In Vitro and In Vivo Activity against Hepatitis C Virus

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Takebe, Yutaka ^a   Saucedo, Carrie J ^b   Lund, Garry ^c   Uenishi, Rie ^a   Hase, Saiki ^a   Tsuchiura, Takayo ^a   Kneteman, Norman ^c   Ramessar, Koreen ^d   Tyrrell, D Lorne J ^c   Shirakura, Masayuki ^a   Wakita, Takaji ^a   McMahon, James B ^d   O'Keefe, Barry R ^d  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^b SAIC FREDERICK INC   (United States)

^c KMT Hepatech   (Canada)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; GLYCOPROTEIN E1; GLYCOPROTEIN E2; GRIFFITHSIN; LECTIN; SCYTOVIRIN; UNCLASSIFIED DRUG; GLYCOPROTEIN E2, HEPATITIS C VIRUS; PLANT LECTIN; PROTEIN BINDING; VIRUS ENVELOPE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CYANOBACTERIUM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ISOLATION; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG TOLERABILITY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN BINDING; RED ALGA; VIRUS ENTRY; VIRUS TITRATION; VIRUS VIRULENCE; ANIMAL; CELL LINE; CHEMICAL STRUCTURE; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; GREEN ALGA; HEPACIVIRUS; METABOLISM; PHYSIOLOGY; PROTEIN CONFORMATION; VIROLOGY; VIRUS LOAD; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE; CHLOROPHYTA; DISEASE MODELS, ANIMAL; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; MICE; MODELS, MOLECULAR; PLANT LECTINS; PROTEIN BINDING; PROTEIN CONFORMATION; RHODOPHYTA; VIRAL ENVELOPE PROTEINS; VIRAL LOAD; VIRUS INTERNALIZATION; VIRUS REPLICATION;

EID: 84877982057     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0064449     Document Type: Article

References (44)

1. Lindenbach BD, Thiel H-J, Rice CM (2007) Flaviviridae: the viruses and their replication. In D.M. Knipe et al. (ed.), Fields Virology, 5th ed. Philadelphia:Lippincott Williams & Wilkins 1101-1152.
2. Ghany MG, Strader DB, Thomas DL, Steef LB, (2009) Diagnosis, management and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-1374.
3. Michaels AJ, Nelson DR, New therapies in the management of hepatitis C virus. Curr Opinion Gastroenterology 26: 196-201.
4. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, et al. (2002) Pegiterferon alpha-2a plus ribavirin for chronic hepatitis C infection. N Engl J Med 347: 975-982.
5. Sarrazin C, Zeuzem S, (2010) Resistance to direct antiviral agents in patients with hepatitis C infection. Gastroenterology 138: 447-462.
6. Vermehren J, Sarrazin C, (2011) New HCV therapies on the horizon. Clin Microbiol Infect 17: 122-134.
7. Naggie S, Patel K, McHutchison J, (2010) Hepatitis C virus directly acting antivirals: current developments with NS3/4AHCV serine protease inhibitors. J Antimicrob Chemother 65: 2063-2069.
8. Pol S, Everson GT, Ghalib R, Rustgi V, Martorell C, et al. (2010) Once-daily NS5a inhibitor (BMS-790052) plus peginterferon-alpha-2a and ribaviron produces high rates of extended rapid virological response in treatment-naïve HCV-genotype I subjects. J Hepatol 52: S462.
9. Davis DL, Nelson DR, Terrault N, Pruett TL, Schiano TD, et al. (2005) A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis c immune globulin (Civacir) in liver transplant recipients. Liver Transpl 11: 941-949.
10. Schiano TD, Charlton M, Younossi Z, Galun E, Pruett T, et al. (2006) Monoclonal antibody HCV-AbXTL68 in patients undergoing liver transplantation for HCV: results of Phase 2 randomized study. Liver Transpl 12: 1381-1389.
11. Op De Beeck A, Cocquerel L, Dubuisson J, (2004) Biogenesis of hepatitis C envelope glycoproteins. J Virol 78: 2994-3002.
12. Goffard A, Dubuisson J, (2003) Glycosylation of hepatitis C virus envelope proteins. Biochimie 85: 295-31.
13. Krieger SE, Zeisel MB, Davis C, Thumann C, Harris HJ, et al. (2010) Inhibition of hepatitis C virus infection by anti-claudin-1 antibodies is mediated by neutralization of E2-CD81-claudin-1 associations. Hepatology 51: 1144-57.
14. Bartosch B, Vitelli A, Granier C, Goujon C, Dubuisson J, et al. (2003) Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor. J Biol Chem 278: 41624-41630.
15. Goffard A, Callens N, Bartosch B, Wychowski C, Cosset F-L, et al. (2005) Role of N-linked glycans in the functions of hepatitis C virus envelope glycoproteins. J Virol 79: 8400-8409.
16. Slater-Handshy T, Droll DA, Fan X, Di Bisceglie AM, Chambers TJ, (2004) HCV E2 glycoprotein: mutagenesis of N-linked glycosylation sites and its effects on E2 expression and processing. Virology 319: 36-48.
17. Helle F, Goffard A, Morel V, Duverlie G, McKeating J, et al. (2007) The neutralizing activity of anti-hepatitis C virus antibodies is modulated by specific glycans on the E2 envelope protein. J Virol 81: 8101-8111.
18. Zeisel MB, Fofana I, Fafi-Kremer S, Baumert TF, (2011) Hepatitis C virus entry into hepatocytes: molecular mechanisms and targets for antiviral therapies. J Hepatol 54: 566-576.
19. Polyak SJ, Morishima C, Shuhart MC, Wang CC, Liu Y, et al. (2007) Inhibition of T-cell inflammatory cytokines, hepatocyte NF-kB signaling, and HCV infection by standardized silymarin. Gastroenterology 132: 1925-1936.
20. Zhang H, Rothwangl K, Mesecar AD, Sabahi A, Rong L, et al. (2009) Lamiridosins, hepatitis C virus entry inhibitors from Lamium album. J Nat Prod 72: 2158-2162.
21. Helle F, Wychowski C, Vu-Dac N, Gustafson KR, Voisset C, et al. (2006) Cyanovirin-N inhibits hepatitis C viral entry by binding to envelope protein glycans. J Biol Chem 281: 25177-25183.
22. Bokesch HR, O'Keefe BR, McKee TC, Pannell LK, Patterson GM, et al. (2003) A potent novel anti-HIV protein from the cultured cyanobacterium Scytonema varium. Biochemistry 42: 2578-2584.
23. Mori T, O'Keefe BR, Sowder RC 2nd, Bringans S, Gardella R, et al. (2005) Isolation and characterization of griffithsin, a novel HIV-inactivating protein, from the red alga Griffithsia sp. J Biol Chem 280: 9345-9353.
24. McFeeters RL, Xiong C, O'Keefe BR, Bokesch HR, McMahon JB, et al. (2007) The novel fold of scytovirin reveals a new twist for antiviral entry inhibitors. J Mol Biol 369: 451-61.
25. Moulaei T, Botos I, Ziółkowska NE, Bokesch HR, Krumpe LR, et al. (2007) Atomic-resolution crystal structure of the antiviral lectin scytovirin. Protein Sci 16: 2756-60.
26. Ziółkowska NE, O'Keefe BR, Mori T, Zhu C, Giomarelli B, et al. (2006) Domain-swapped structure of the potent antiviral protein griffithsin and its mode of carbohydrate binding. Structure 14: 1127-35.
27. Meuleman P, Albecka A, Belouzard S, Vercauteren K, Verhoye L, et al. (2011) Griffithsin has antiviral activity against hepatitis C virus. Antimicrob Agents Chemother 55: 5159-67.
28. Kato T, Date T, Miyamoto M, Sugiyama M, Tanaka Y, et al. (2005) Detection of anti-hepatitis C virus effects of interferon and ribavirin by a sensitive replicon system. J Clin Microbiol 43: 5679-84.
29. Bartosch B, Dubuisson J, Cosset F-L, (2003) Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J Exp Med 197: 633-642.
30. Meunier J-C, Fournillier-Jacob A, Choukhi A, Cahour A, Cocquerel L, et al. (1999) Analysis of the glycosylation sites of hepatitis C virus (HCV) glycoprotein E1 and the influence of E1 glycans on the formation of the HCV glycoprotein complex. J Gen Virol 80: 887-896.
31. Zhang M, Gaschen B, Blay W, Foley B, Haigwood N, et al. (2004) Tracking global patterns of N-linked glycosylation site variation in highly variable viral glycoproteins: HIV, SIV, and HCV envelopes and influenza hemagglutinin. Glycobiol 14: 1229-1246.
32. Goffard A, Callens N, Bartosch B, Wychowski C, Cosset F-L, et al. (2005) Role of N-linked glycans in the functions of hepatitis C virus envelope glycoproteins. J Virol 79: 8400-8409.
33. Vieyres G, Thomas X, Descamps V, Duverlie G, Patel AH, et al. (2010) Characterization of the envelope glycoproteins associated with infectious hepatitis C virus. J Virol 84: 10159-68.
34. Kouokam JC, Huskens D, Schols D, Johannemann A, Riedell SK, et al. (2011) Investigation of griffithsin's interactions with human cells confirms its outstanding safety and efficacy profile as a microbicide candidate. PLoS ONE 6: e22635.
35. Barth H, Robinet E, Liang TJ, Baumert TF, (2008) Mouse models for the study of HCV infection and virus-host interactions. J Hepatol 49: 134-142.
36. Feld JJ, Hoofnagle JH, (2005) Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 436: 967-972.
37. Susser S, Vermehren J, Forestier N, Welker MW, Grigorian N, et al. (2011) Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir. J Clin Virol 52: 321-7.
38. Halfon P, Locarnini S, (2011) Hepatitis C virus resistance to protease inhibitors. J Hepatol 55: 192-206.
39. Mori T, Gustafson KR, Pannell LK, Shoemaker RH, et al. (1998) Recombinant production of cyanovirin-N, a potent human immunodeficiency virus-inactivating protein derived from a cultured cyanobacterium. Protein Expr Purif 12: 151-8.
40. Xiong C, O'Keefe BR, Botos I, Wlodawer A, McMahon JB, (2006) Overexpression and purification of scytovirin, a potent, novel anti-HIV protein from the cultured cyanobacterium Scytonema varium. Protein Expr Purif 46: 233-9.
41. Giomarelli B, Schumacher KM, Taylor TE, Sowder RC 2nd, Hartley JL, et al. (2006) Recombinant production of anti-HIV protein, griffithsin, byauto-induction in a fermentor culture. Protein Expr Purif 47: 194-202.
42. O'Keefe BR, Vojdani F, Buffa V, Shattock RJ, Montefiori DC, et al. (2009) Scaleable manufacture of HIV-1 entry inhibitor griffithsin and validation of its safety and efficacy as a topical microbicide component. Proc Natl Acad Sci U S A 106: 6099-104.
43. Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, et al. (2005) Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Medicine 11: 791-6.
44. Sakamoto H, Okamoto K, Aoki M, Kato H, Katsume A, et al. (2005) Host sphingolipid biosynthesis as a target for hepatitis C virus therapy. Nat Chem Biol 1: 333-337.